PLASMODIUM VIVAX MSP-3 AND MSP-9 AS VACCINE IMMUNOGENS

这个子项目是许多研究子项目中的一个 由NIH/NCRR资助的中心赠款提供的资源。子项目和 研究者（PI）可能从另一个NIH来源获得了主要资金， 因此可以在其他CRISP条目中表示。所列机构为 研究中心，而研究中心不一定是研究者所在的机构。 该项目的广泛的长期目标是开发间日疟原虫裂殖子表面蛋白-3（PvMSP-3）和PvMSP-9重组蛋白的成员作为候选疟疾疫苗产品。该实验室最初鉴定、表达和表征了这些蛋白质及其作为疟疾候选疫苗的潜力。我们已经鉴定和表征了PvMSP 3家族的其他成员（总共11个基因），并且已经生产了代表每个基因的重组产物用于生物化学表征。重组产物在原核系统中表达，并已用于生产多克隆兔抗血清，识别每个PvMSP 3蛋白。为了与我们评价人体天然免疫应答的目的保持一致，生产、纯化并测试了代表PvMSP 3 α（PvMSP-3a）蛋白的5种重组产物（Lima-Junior et al 2008）。最后，代表PvMSP 3 α（PvMSP-3a）蛋白的相同五种产品在玻利维亚赛米里猴中进行了安全性、免疫原性和有效性测试，目前正在分析结果。这些灵长类动物对间日疟原虫感染易感，可以很好地用作直接攻击模型。

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. The broad long-term objective of this project is to develop members of the Plasmodium vivax merozoite surface protein-3 (PvMSP-3 ) and PvMSP-9 recombinant proteins as candidate malaria vaccine products. This laboratory originally identified, expressed, and characterized these proteins and their potential as malaria vaccine candidates. We have identified and characterized additional members of the PvMSP3 family (total of eleven genes) and recombinant products representing each gene have been produced for biochemical characterization. The recombinant products were expressed in a prokaryotic system and have been used to produce polyclonal rabbit antisera which recognize each PvMSP3 protein. In keeping with our objective to evaluate the native immune response in humans, five recombinant products representing the PvMSP3 alpha (PvMSP-3a) protein were produced, purified and tested (Lima-Junior et al 2008). Finally, the same five products representing the PvMSP3 alpha (PvMSP-3a) protein were tested for safety, immunogenicity and efficacy in Saimiri boliviensis monkeys, and the results are currently being analyzed. These primates are susceptible to P. vivax infections and can serve very well as a direct challenge model.